An integrative spatial multi-omics strategy, combining bulk and single-cell RNA sequencing, subcellular-resolution spatial transcriptomics, and spatial proteomics on tissues from TACE-treated and treatment-naïve HCC patients, presents a potential therapeutic strategy to overcome TACE resistance and improve clinical outcomes.
Abstract
To elucidate the cellular and molecular mechanisms underlying therapeutic resistance (refractoriness) following transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) by comprehensively characterizing the post-treatment tumor microenvironment (TME). We employed an integrative spatial multi-omics strategy, combining bulk and single-cell RNA sequencing, subcellular-resolution spatial transcriptomics, and spatial proteomics on tissues from TACE-treated and treatment-naïve HCC patients. Public datasets were used for prognostic and predictive validation, and key findings were confirmed with multiplex immunofluorescence and in vitro experiments. TACE induced a profoundly hypoxic TME, which drove the selective enrichment of a pro-fibrotic tumor-associated macrophage (TAM) population characterized by high SPP1 expression (SPP1 + TAMs). Spatial mapping demonstrated that these SPP1 + TAMs localize to hypoxic tumor cores, where they remodel the extracellular matrix by producing fibronectin (FN1), establish fibrotic niches, and restrict T-cell activation, thereby orchestrating an immune-excluded microenvironment. The abundance of this macrophage subtype was a robust predictor of TACE resistance. TACE-induced hypoxia promotes a macrophage-driven fibrotic program that is a key determinant of immune evasion and treatment failure in HCC. Targeting this SPP1 + TAM-mediated fibrotic niche presents a potential therapeutic strategy to overcome TACE resistance and improve clinical outcomes.
An integrated single-cell atlas defines a critical POSTN+ CAF–APOE+ macrophage unit that is associated with a fibrotic and immunosuppressive TME in advanced prostate cancer, and suggested conserved enrichment and adverse prognostic impact of this stromal-immune axis across diverse tumor types, though tissue-specific co...
Yangzhou Liu, Ao-Chu Liu, Xing-Lai Dai et al.· Frontiers in Immunology· 0 citations
The CMLS translates spatial immune-exclusion dynamics into a quantifiable metric, outperforming tumor mutational burden in predicting ICB benefits, providing a robust tool for patient stratification in ccRCC.
Zhe Wang, Ying-Jian Wang, Jia-Yi Zhang et al.· Human Genomics· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) confers dismal clinical outcomes largely owing to its robust metastatic propensity, among which liver metastasis accounts for the deadliest metastatic phenotype. The core malignant cell populations governing the onset and outgrowth of PDAC hepatic metastasis, as well as their s...
The results demonstrate that S100A10 is significantly upregulated in HCC and is closely associated with poor prognosis and an immunosuppressive state, and provides a theoretical basis for combinatorial strategies targeting metabolism and immunotherapy.
Jing-Xu Zhang, Gang-Gang Wang, Zhijie Zhou et al.· International Immunopharmaco...· 0 citations
A site-specific regulatory mechanism of the macrophage-endothelial niche is revealed, offering a novel and clinically significant biomarker for CRC prognosis.
Intrahepatic cholangiocarcinoma (ICC) is a rare but highly aggressive primary liver malignancy distinguished by a profoundly heterogeneous tumor microenvironment, which underlies its limited response to targeted and immune-based therapies. Deciphering the cellular composition and intercellular signaling within this com...
Guo-Liang Wang, Hang Meng, Meng Li et al.· Genomics, Proteomics & Bioin...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.